^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Metvixia (methyl aminolevulinate hydrochloride 16.8% cream)

    i
    Other names: MAL cream , CD06809-41
    Associations

    News

    Trials
    Company:
    Galderma
    Drug class:
    Photosensitizer
    Related drugs:
    Associations

    News

    Trials
    9ms
    ADL-PDT Under Routine Clinical Conditions in Patients With Actinic Keratosis (clinicaltrials.gov)
    P=N/A, N=224, Completed, Galderma Laboratorium GmbH | Recruiting --> Completed | N=350 --> 224
    Trial completion • Enrollment change
    |
    Metvixia (methyl aminolevulinate hydrochloride 16.8% cream)
    1year
    New Treatments for Actinic Keratoses of the Scalp (clinicaltrials.gov)
    P=N/A, N=120, Active, not recruiting, Helsinki University Central Hospital | Trial completion date: Jul 2024 --> Dec 2024
    Trial completion date
    |
    Metvixia (methyl aminolevulinate hydrochloride 16.8% cream)
    1year
    A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study (clinicaltrials.gov)
    P3, N=125, Terminated, Galderma R&D | Completed --> Terminated; The study was terminated early as per Sponsor's decision
    Trial termination
    |
    Metvixia (methyl aminolevulinate hydrochloride 16.8% cream)
    over3years
    MAL DL-PDT and Calcitriol for AK treatment of the upper extremities MAL DL-PDT e Calcitriolo per le AK degli arti superiori (clinicaltrialsregister.eu)
    P3, N=36, Ongoing, ASL 1 AVEZZANO-SULMONA-L'AQUILA
    Clinical • New P3 trial
    |
    CTGF (Connective tissue growth factor)
    |
    Metvixia (methyl aminolevulinate hydrochloride 16.8% cream)